Pelthos Therapeutics
PTHS
5 hedge funds and large institutions have $187K invested in Pelthos Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.75% less ownership
Funds ownership: 0.98% → 0.23% (-0.75%)
44% less funds holding
Funds holding: 9 → 5 (-4)
78% less capital invested
Capital invested by funds: $846K → $187K (-$659K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$165K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$447 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$626K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$186K |
| 3 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$14.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.99K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$422 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| $172K | +$165K | +13,671 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $14.1K | +$447 | +37 | +4% |
|
|
3
UBS Group
Zurich,
Switzerland
| $822 | -$422 | -35 | -35% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $107 | -$2.99K | -248 | -96% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $24 | +$12 | +1 | +100% |
|
|
IC
6
Ikarian Capital
Dallas,
Texas
| – | -$626K | -44,085 | Closed |
|
|
BFM
7
Boothbay Fund Management
New York
| – | -$186K | -13,075 | Closed |
|
|
8
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| – | -$14.8K | -1,040 | Closed |
|
|
TCM
9
Tradewinds Capital Management
Bellingham,
Washington
| – | -$284 | -20 | Closed |
|
10
Barclays
London,
United Kingdom
| – | -$77 | -5 | Closed |
|
PTHS Hedge Fund Activity: Q2 2025 in Review
5 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q2 2025, worth a combined $187K — down 78% from $846K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PTHS and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $165K. The largest seller was Ikarian Capital, exiting entirely with an estimated $626K sold.
- 5 institutional investors held Pelthos Therapeutics (PTHS) as of Q2 2025, down from 9 in Q1 2025.
- Funds reported $187K of Pelthos Therapeutics stock for Q2 2025, down 78% quarter-over-quarter.
- 1 fund opened new Pelthos Therapeutics positions in Q2 2025 and 5 closed out, a net change of -4 holders.
- The largest Pelthos Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $165K added.
- The largest Pelthos Therapeutics seller in Q2 2025 was Ikarian Capital, an estimated $626K sold.
Based on aggregated 13F filings for Q2 2025.